AGIOS PHARMACEUTICALS, INC. Increase (Decrease) in Accounts and Other Receivables
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Increase (Decrease) in Accounts and Other Receivables of $0 for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2018-08-02
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2018-06-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2017-12-31 was -$372.00K.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for the quarter ending 2017-09-30 was $80.00K, a 92.65% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for fiscal 2017 was -$2.93M.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for fiscal 2016 was -$275.00K, a 126.44% decline from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for fiscal 2015 was $1.04M, a 55.44% decline from fiscal 2014.
- AGIOS PHARMACEUTICALS, INC. increase (decrease) in accounts and other receivables for fiscal 2014 was $2.33M.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $0.00 10-Q · filed 2018-08-02 | -$372.00K derived: sum of 3 quarters · filed 2018-08-02 | -$292.00K derived: sum of 4 quarters · filed 2018-08-02 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-04 | -$372.00K derived: sum of 2 quarters · filed 2018-05-04 | -$292.00K derived: sum of 3 quarters · filed 2018-05-04 | -$2.95M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-12-31 | -$372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | -$292.00K derived: sum of 2 quarters · filed 2018-02-14 | -$2.95M derived: sum of 3 quarters · filed 2018-08-02 | -$2.93M 10-K · filed 2018-02-14 |
| 2017-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$2.58M derived: sum of 2 quarters · filed 2018-08-02 | -$2.56M 10-Q · filed 2017-11-01 | -$2.56M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-06-30 | -$2.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$2.64M 10-Q · filed 2018-08-02 | -$2.64M derived: sum of 3 quarters · filed 2018-08-02 | -$1.55M derived: sum of 4 quarters · filed 2018-08-02 |
| 2017-03-31 | $24.00K 10-Q · filed 2018-05-04 | $20.00K derived: sum of 2 quarters · filed 2018-05-04 | $1.11M derived: sum of 3 quarters · filed 2018-05-04 | $2.55M derived: sum of 4 quarters · filed 2018-05-04 |
| 2016-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $1.08M derived: sum of 2 quarters · filed 2018-02-14 | $2.53M derived: sum of 3 quarters · filed 2018-02-14 | -$275.00K 10-K · filed 2018-02-14 |
| 2016-09-30 | $1.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $2.53M derived: sum of 2 quarters · filed 2017-11-01 | -$271.00K 10-Q · filed 2017-11-01 | $110.00K derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-06-30 | $1.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$1.36M 10-Q · filed 2017-08-08 | -$979.00K derived: sum of 3 quarters · filed 2018-02-14 | -$3.27M derived: sum of 4 quarters · filed 2018-02-14 |
| 2016-03-31 | -$2.80M 10-Q · filed 2017-05-04 | -$2.42M derived: sum of 2 quarters · filed 2018-02-14 | -$4.71M derived: sum of 3 quarters · filed 2018-02-14 | -$6.34M derived: sum of 4 quarters · filed 2018-02-14 |
| 2015-12-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | -$1.91M derived: sum of 2 quarters · filed 2018-02-14 | -$3.53M derived: sum of 3 quarters · filed 2018-02-14 | $1.04M 10-K · filed 2018-02-14 |
| 2015-09-30 | -$2.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | -$3.91M derived: sum of 2 quarters · filed 2016-11-03 | $659.00K 10-Q · filed 2016-11-03 | |
| 2015-06-30 | -$1.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $2.95M 10-Q · filed 2016-08-08 | ||
| 2015-03-31 | $4.57M 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $2.33M 10-K · filed 2017-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |